Orodax (Solifenacin Succinate)

Orodax is a bladder‑control medication that works on the urinary storage pathway.

• Overactive bladder: Improves urgency, frequency and nocturia.
• Neurogenic detrusor overactivity: Reduces involuntary bladder contractions.
• Detrusor instability: Helps stabilize bladder muscle activity.

• Solifenacin succinate selectively binds to M3 muscarinic receptors in the smooth muscle of the urinary bladder, blocking acetylcholine‑mediated contractions. This inhibition reduces involuntary detrusor muscle activity, allowing the bladder to store urine more effectively and decreasing symptoms of urgency and frequency.

Side effects reported with solifenacin are generally mild to moderate and vary by individual.

Common Side Effects

• Dry mouth: Reduced salivation leading to a feeling of thirst.
• Constipation: Slowed intestinal transit.
• Blurred vision: Temporary visual disturbances.
• Urinary retention: Difficulty initiating urination.
• Headache: Mild to moderate head pain.
• Dizziness: Light‑headed sensation.

Serious or Rare Side Effects

• Severe urinary retention requiring catheterisation.
• Acute angle‑closure glaucoma.
• Allergic reactions: Rash, itching, swelling or anaphylaxis.
• Tachycardia: Rapid heart rate.
• Hepatic enzyme elevation.
• Persistent severe constipation.

When prescribing Orodax, clinicians should consider several safety aspects.

• Renal impairment: Dose adjustment may be needed.
• Hepatic impairment: Use with caution.
• Elderly patients: Monitor for anticholinergic burden.
• Concomitant anticholinergics: Assess cumulative effect.
• Narrow‑angle glaucoma: Contra‑indicated.
• Store at ambient temperature: Keep in original packaging, protect from moisture.

Orodax may interact with other medicines that influence cholinergic pathways.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: May increase solifenacin levels.
• P‑Mediated P‑R   .

Moderate   t  t .